USA, Europe give nod to ixekizumab for PsA

medwireNews: The indication for ixekizumab has been expanded to include psoriatic arthritis (PsA) in the USA and Europe.

The interleukin-17A inhibitor has been approved for the treatment of plaque psoriasis since 2016. It is now approved by the US FDA for the treatment of adult patients with active PsA, while the EMA has recommended its approval for the treatment of active PsA in adults with an inadequate response or intolerance to one or more DMARDs.

Ixekizumab is administered by subcutaneous injection and can be given alone or in combination with methotrexate.

By Claire Barnard

medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group

See also:

• SPIRIT-P2 results support ixekizumab for PsA patients with inadequate anti-TNF response
• Extended benefits of ixekizumab treatment in patients with PsA